Alveogene

AlveoGene develops inhaled gene therapies that aim to treat rare respiratory diseases by delivering therapy directly to the lungs. Its proprietary InGenuiTy lentiviral platform, licensed from the UK Respiratory Gene Therapy Consortium, is designed for high transduction of lung epithelial cells via nebuliser or neonatal instillation and can be readministered without losing efficacy. The company was created by Oxford Science Enterprises, Harrington Discovery Institute, and Old College Capital with six GTC scientist co-founders, and is advancing candidates for conditions such as surfactant protein B deficiency.